JP2017178895A - Aqueous adhesive patch containing flurbiprofen - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an aqueous adhesive patch containing flurbiprofen having excellent drug permeability and drug stability, which is obtained by dissolving a slightly water-soluble flurbiprofen in a water-containing adhesive base.SOLUTION: There is provided an aqueous adhesive patch containing flurbiprofen having excellent drug permeability and drug stability which is obtained by blending a specific amount of a polyoxyethylene sorbitan fatty acid ester and a sorbitan sesquioleate to dissolve flurbiprofen as an active ingredient in an aqueous adhesive patch.SELECTED DRAWING: None

Description

  The present invention relates to a flurbiprofen-containing hydrous patch excellent in transdermal absorbability and drug stability by dissolving flurbiprofen, which is sparingly soluble in water, in a hydrous adhesive base. More specifically, the present invention relates to a water-based adhesive base containing flurbiprofen, which is an active ingredient, by blending a specific amount of polyoxyethylene sorbitan fatty acid ester and sorbitan sesquioleate, which are nonionic surfactants. The present invention relates to a flurbiprofen-containing water-containing patch excellent in drug permeability and drug stability.

  Flurbiprofen, which is one of non-steroidal anti-inflammatory drugs (NSAIDs), is rheumatoid arthritis, osteoarthritis, low back pain, cervical arm syndrome, shoulder shoulder arthritis, toothache It is widely used as an effective anti-inflammatory and analgesic agent for acute upper respiratory tract inflammation, post-surgery, post-traumatic, and post-extraction. However, when NSAIDs are administered orally, side-effects such as gastric mucosal irritation and ulceration in the small intestine may occur. For this reason, as a means for reducing side effects, external patches such as a patch for a water-based patch and a tape for a non-aqueous patch that are administered through the skin have been developed. In particular, a poultice contains a large amount of water in the adhesive base, and the affected part is cooled by the evaporation of the water, so that it can be expected to have further anti-inflammatory and analgesic effects.

  Since flurbiprofen is hardly soluble in water, it has been difficult to formulate a hydrous patch such as a poultice. Therefore, in order to dissolve flurbiprofen in the base, increase the permeability of the drug, and promote percutaneous absorption, it is necessary to use a solubilizer and a solubilizer in combination. For example, in order to improve transdermal absorbability, a patch using crotamiton has been developed (Patent Document 1). A patch having improved transdermal absorbability with an O / W emulsion containing crotamiton has also been developed (Patent Document 2).

  However, by incorporating crotamiton, the transdermal absorbability can be increased, but there is a problem that the stability of flurbiprofen in the base is deteriorated. In order to improve the stability of flurbiprofen, a patch containing 2-mercaptobenzimidazole, which is an antioxidant, has been developed (Patent Document 3 and Patent Document 4), but has sufficient drug stability. It was not obtained, and the development of the preparation that achieved the purpose has not been achieved.

Therefore, it has been desired to develop a flurbiprofen-containing water-containing patch excellent in drug permeability and drug stability by dissolving flurbiprofen, which is an active ingredient, in a water-containing adhesive base.

JP2014-028767 JP-A-6-247847 JP 2002-128701 A JP 2010-090099

  The object of the present invention has been made in view of the above-mentioned situation. Flurbiprofen, which is poorly soluble in water and dissolved in a water-containing adhesive base, has excellent drug permeability and drug stability. It is to provide a water-containing patch containing water.

As a result of intensive studies to solve the above problems, the present inventors have formulated flurbiprofen, which is an active ingredient, into a water-based adhesive by blending a specific amount of polyoxyethylene sorbitan fatty acid ester and sorbitan sesquioleate. The present inventors have found that a flurbiprofen-containing hydrous patch excellent in drug permeability and drug stability can be obtained by dissolving in a base, and the present invention has been completed based on this finding.
That is, this invention is shown to the following (1) to (3).
(1) A flurbiprofen-containing hydrous patch comprising 0.5 to 1.0% by weight of polyoxyethylene sorbitan fatty acid ester and sorbitan sesquioleate.
(2) The flurbiprofen-containing hydrous patch according to (1), wherein the polyoxyethylene sorbitan fatty acid ester is at least one selected from polysorbate 20, polysorbate 60, and polysorbate 80.
(3) The flurbiprofen-containing hydrous adhesive patch according to (1) or (2), wherein the hydrous adhesive base further contains water, a water-soluble polymer, a crosslinking agent, and a moisturizing / wetting agent. Agent.

  As described above, the present invention provides a flurbiprofen-containing hydrous patch excellent in drug permeability and drug stability by dissolving flurbiprofen, which is an active ingredient, in a hydrous adhesive base. be able to.

  Hereinafter, the flurbiprofen-containing hydrous patch of the present invention will be described in detail. Note that the examples described in the present specification do not particularly limit the present invention.

The present invention is an external patch containing flurbiprofen in a water-containing adhesive base such as a poultice.
The “drug stability” of the present invention refers to a case where the test preparation is placed in an aluminum bag, sealed, stored at 60 ° C. for 3 weeks, and the flurbiprofen content at the start of storage is 100%. It means the content percentage after 3 weeks. Those having a content rate of 85% or more after storage at 60 ° C. for 3 weeks were considered excellent in drug stability.

The “drug permeation amount” of the present invention refers to a receiver solution from a test preparation when a permeation test is conducted for 3 hours using a diffusion cell and a phosphate buffered saline as a receiver solution. means migrated amount of drug to drug permeation amount after 3 hours was excellent in percutaneous absorbability of 20 [mu] g / cm ² or more.

  The content of flurbiprofen, which is an active ingredient in the flurbiprofen-containing water-containing patch of the present invention, is not particularly limited as long as it can be formulated, but it is 0.1 wt% to 5 wt%. Preferably there is. If it is less than 0.1% by weight, the medicinal effect is insufficient, and if it exceeds 5% by weight, it is not economical and not preferred.

  Examples of the polyoxyethylene sorbitan fatty acid ester used in the present invention include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, etc., and can be used alone or in combination of two or more, preferably polysorbate 20, polysorbate 60 and polysorbate 80. The content of the polyoxyethylene sorbitan fatty acid ester is preferably 0.5% by weight to 1.0% by weight. More preferably, it is 0.6% by weight to 0.9% by weight. If it is less than 0.5% by weight, the stability of the drug is deteriorated, which is not preferable. On the other hand, if it exceeds 1.0% by weight, it is not preferred because it affects physical properties such as stickiness.

  The sorbitan sesquioleate used in the present invention is not particularly limited as long as it is medically or pharmaceutically acceptable.

As a component of the water-containing pressure-sensitive adhesive base of the present invention, a known one or a newly provided one may be used, and there is no particular limitation.
The flurbiprofen-containing hydrous patch of the present invention requires water, a water-soluble polymer, a cross-linking agent, and a moisturizing / wetting agent that are used to prepare the hydrous adhesive base.

  Examples of the water used in the present invention include purified water, sterilized water, natural water, normal water, and water for injection. These can be used alone or in combination of two or more, but purified water is preferred.

  Examples of the water-soluble polymer used in the present invention include gelatin, casein, pullulan, dextran, dextrin, chitin, chitosan, agar, pectin, β-glucan, sodium alginate, soluble starch, carboxy starch, carmellose, carmellose sodium, Methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylethylcellulose, nitrocellulose, carboxymethylamylose, polyvinyl alcohol, polyethylene oxide, polyacrylic acid, sodium polyacrylate, polyacrylamide, polyvinylpyrrolidone, carboxyvinyl polymer, Polyvinyl ether, etc. are mentioned, alone or in combination of two or more So it can be used.

  Examples of the crosslinking agent used in the present invention include aluminum hydroxide, aluminum chloride, aluminum hydroxide gel, hydrous aluminum silicate, synthetic aluminum silicate, aluminum acetate, aluminum lactate, aluminum stearate, calcium hydroxide, calcium chloride, Inorganic polyvalent metal compounds such as magnesium chloride, aluminum chloride, aluminum sulfate, aluminum ammonium sulfate, potassium aluminum sulfate, magnesium aluminate metasilicate, and dihydroxyaluminum aminoacetate can be used, and these can be used alone or in combination of two or more.

  Examples of the moisturizing / wetting agent used in the present invention include propylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, isobutylene glycol, glycerin, concentrated glycerin, diglycerin, sorbitol, polyethylene glycol, Polyhydric alcohols such as polypropylene glycol and xylitol can be mentioned, and these can be used alone or in combination of two or more.

  The flurbiprofen-containing hydrous patch of the present invention is not limited to the above-mentioned essential components, but is allowed to produce various components that do not impair the effects of the present invention, that is, a pH adjuster, a fragrance / cooling agent. An agent, a warming agent, an excipient, an absorption accelerator, a surfactant, a chelating agent, an antioxidant, an antiseptic, and the like can be appropriately blended.

  Examples of pH adjusters include acids such as acetic acid, formic acid, lactic acid, tartaric acid, oxalic acid, benzoic acid, glycolic acid, malic acid, citric acid, succinic acid, fumaric acid, phosphoric acid, hydrochloric acid, nitric acid, sulfuric acid, and the like. Salt of sodium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, monomethanolamine, mono Ethanolamine, monopropanolamine, dimethanolamine, diethanolamine, dipropanolamine, trimethanolamine, triethanolamine, isopropanolamine, tripropanolamine and other amines, arginine, aqueous ammonia, carbonate group Bleed, sodium hydrogen carbonate, and ammonium carbonate and the like, can be used alone or in combination.

  Examples of fragrances and refreshing agents include mint oil, mint oil, cinnamon oil, clove oil, fennel oil, castor oil, turpentine oil, eucalyptus oil, orange oil, lavender oil, lemon oil, rose oil, lemongrass oil, Fragrances such as plant extract such as rosemary, sage, etc., l-menthol, camphor, thymol, daikyo oil, chimian oil, henoposi oil, yamadine oil, touka oil, bergamot oil, citronella oil, camphor oil, geranium oil Examples of the cooling agent include N-ethyl-p-menthane-carboxamide, p-menthane-3,8-diol, l-isopulegol, and l-menthyl glyceryl ether, which can be used alone or in combination of two or more. .

  Examples of the warming agent include capsaicin, dihydroxycapsaicin, capsanthin, capsaicinoid, capsicoside, capsicum extract, capsicum tincture, capsicum powder, nicotinic acid benzyl, nicotinic acid β-butoxyethyl, N-acylvanilamide, nonylic acid vanillamide , Vanillyl alcohol alkyl ether and the like, and may be used alone or in combination of two or more.

  Examples of excipients include talc, zinc oxide, hydrous silica, magnesium carbonate, calcium hydrogen phosphate, magnesium silicate, calcium silicate, aluminum metasilicate, calcium sulfate, calcium phosphate, calcium carbonate, magnesium carbonate, diatomaceous earth, Examples include kaolin, silicic anhydride, titanium oxide, and the like. These can be used alone or in combination of two or more.

  Examples of the absorption promoter include diisopropyl adipate, lecithin, squalane, squalene, azone, l-menthol, polyethylene glycol, isopropyl myristate, dimethyl sulfoxide, peppermint oil, eucalyptus oil, d-limonene, dl-limonene and the like. These can be used alone or in combination of two or more.

  Examples of the surfactant include sorbitan fatty acid esters (other than sorbitan sesquioleate), glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, polyoxyethylene glycerin fatty acid esters, sorbitol fatty acid esters, polyoxyethylene sorbitol fatty acid esters. , Ester compounds such as polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene stearyl ether, polyoxyethylene tridecyl ether, polyoxyethylene nonylphenyl ether, polyoxyethylene octylphenyl ether, polyoxyethylene alkylphenyl ether , Alkylallyl formaldehyde condensed polyoxyethylene ether, polyoxyethylene Ether compounds such as reoxypropyl alkyl ether, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene octadecylamine, polyoxyethylene polyoxypropylene block copolymer, polyoxyethylene alkylamine, sodium dioctylsulfosuccinate, Alkyl sulfate salts, 2-ethylhexyl alkyl sulfate sodium salt, sodium normal dodecylbenzenesulfonate, hexadecyltrimethylammonium chloride, octadecyldimethylbenzylammonium chloride, polyoxyethylene dodecyl monomethylammonium chloride, etc., alone or in combination of two or more Can be used.

  Examples of the chelating agent include edetic acid, oxalic acid, lactic acid, citric acid, acetic acid, tartaric acid, and salts thereof, and can be used alone or in combination of two or more.

  Examples of the antioxidant include ascorbic acid, propyl gallate, butylhydroxyanisole, dibutylhydroxytoluene, nordihydroguaiaretic acid, tocopherol, and tocopherol acetate, which can be used alone or in combination of two or more. .

  Examples of preservatives include thymol, isopropylmethylphenol, benzoic acid, methyl benzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, benzyl alcohol, benzalkonium chloride, benzethonium chloride, and the like. It can be used alone or in combination of two or more.

  As the support for the flurbiprofen-containing hydrous patch, one that does not affect the permeability and stability of the drug is desirable.For example, polyethylene, polyethylene terephthalate, polyvinyl chloride, polyvinylidene chloride, polypropylene, polybutadiene, Stretchable or non-stretchable porous material, foamed material, woven fabric using polyurethane, polyvinyl acetate, nylon, acrylic, cotton, rayon, acetate, ethylene vinyl acetate copolymer alone or in combination of two or more kinds Nonwoven fabrics can be used, and those having elasticity are preferred from the viewpoint of adhesion to the skin.

  Further, as the release film for covering the water-containing adhesive base of the flurbiprofen-containing water-containing patch, one that does not adsorb the drug is desirable, for example, polyethylene, polyethylene terephthalate, polyvinyl chloride, polyvinylidene chloride, polypropylene, etc. These may be used alone or in combination of two or more. Moreover, in order to control the adhesiveness between the release film and the water-containing adhesive base, corona discharge treatment, chemical oxidation treatment, ozone treatment, undercoating treatment, and embossing treatment may be performed as necessary.

  When the flurbiprofen-containing hydrous patch of the present invention is produced, it can be produced by a conventionally known conventional method or a method newly provided in the future. As a typical production method thereof, a composition dissolved or dispersed in flurbiprofen, polyoxyethylene sorbitan fatty acid ester, sorbitan sesquioleate and an absorption accelerator is used as a water-soluble polymer, a crosslinking agent, and a pH adjusting agent. In addition, a water-containing adhesive base is prepared by thoroughly stirring and mixing with a fragrance / cooling agent, a moisturizing / wetting agent and a chelating agent. Apply the water-based adhesive base on the support and bond it to the release film, or apply the water-based adhesive base to the release film and then bond the support to the water-based adhesive Make it an agent. The water-containing patch obtained by these methods can be produced by cutting into a desired size.

Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
Example 1
Based on the formulation shown in Table 1, it was prepared by the method of Preparation Method 1 described later to obtain the flurbiprofen-containing hydrous patch 1 of the present invention. When the obtained flurbiprofen-containing hydrous patch 1 was subjected to a drug stability test according to Test Example 1, the drug content% was 87.8%. Further, the drug permeability when the drug permeability test was conducted according to Test Example 2 was 33.7 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Preparation method 1)
Flurbiprofen was dissolved and dispersed in polysorbate 80 and sorbitan sesquioleate to prepare Preparation A. Carmellose sodium, partially neutralized polyacrylic acid, dry aluminum hydroxide gel, and sodium edetate were dissolved and dispersed in concentrated glycerin to prepare Preparation B. Gelatin was dissolved in purified water heated to about 40 ° C. to prepare a gelatin solution.
Preparation A was added to Preparation B and mixed well, then a gelatin solution was added and mixed until uniform to obtain a hydrous adhesive base. The obtained water-containing adhesive base is spread on a nonwoven fabric so as to be 12 g / 10 × 14 cm, a polyethylene film is bonded as a release film, cut into a desired size, and a flurbiprofen-containing water-containing patch Got. The obtained flurbiprofen-containing hydrous patch was placed in an aluminum bag, sealed and stored at 25 ° C.

(Test Example 1)
Drug stability test The flurbiprofen-containing hydrous patch of Example 1 described above, the flurbiprofen-containing hydrous patch of Examples 2 to 5 described later, and the hydrous patch of Comparative Examples 1 to 6 were used. Then, a drug stability test was conducted by the following method.
One test preparation was placed in an aluminum bag, sealed, and stored at 60 ° C. for 3 weeks. The flurbiprofen content at the start of storage and after 3 weeks was measured by high performance liquid chromatography. The content% after 3 weeks was calculated when the flurbiprofen content at the start of storage was 100%.

(Test Example 2)
Drug Permeability Test Using the flurbiprofen-containing hydrous patch of Example 1 described above, the flurbiprofen-containing hydrous patch of Examples 3 to 5 described later, and the hydrous patch of Comparative Examples 1 to 3 were used. Then, a drug permeability test was conducted by the following method.
After the test preparation was punched out with a punch having a diameter of 10 mm, the release film was removed and attached to a silicon film having a thickness of 0.2 mm and attached to a diffusion cell. The receiver side of the diffusion cell was filled with phosphate buffered saline (pH 7.4) and kept stirring until the end of the test. The jacket temperature of the diffusion cell was kept at 37 ° C. Sampling was performed 3 hours after the start of the test, the amount of drug permeated was determined by high performance liquid chromatography, and the amount of drug permeation per unit area was calculated.

(Test Example 3)
Test for remaining plaster on release film The flurbiprofen-containing hydrous patch of Example 1 described above, the flurbiprofen-containing hydrous patch of Examples 2 to 5 described later, and the hydrous systems of Comparative Examples 1-7 Using the patch, a paste remaining test on the release film was performed by the following method.
The test preparation stored at 25 ° C. for 1 week was taken out and the release film was peeled off. When the plaster did not remain on the release film, it was evaluated as ◯, and when it remained, it was evaluated as ×.

(Example 2)
Exactly the same preparation method as in Example 1 was repeated except that polysorbate 80 was changed from 0.5% by mass to 1.0% by mass in Example 1, and thus a flurbiprofen-containing hydrous patch 2 was obtained. When the obtained flurbiprofen-containing hydrous patch 2 was subjected to a drug stability test according to Test Example 1, the drug content% was 91.2%. Moreover, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Example 3)
In Example 1, the exact same preparation method as Example 1 except that the polysorbate 80 was changed from 0.5% by mass to 1.0% by mass and the sorbitan sesquioleate was changed from 0.05% by mass to 0.1% by mass. Repeatedly, flurbiprofen-containing hydrous patch 3 was obtained. When the obtained flurbiprofen-containing hydrous patch 3 was subjected to a drug stability test according to Test Example 1, the drug content% was 92.2%. Further, the drug permeability when the drug permeability test was conducted according to Test Example 2 was 23.4 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

Example 4
In Example 1, the same preparation as in Example 1 except that 0.5% by mass of polysorbate 80 was changed to 1.0% by mass of polysorbate 20 and sorbitan sesquioleate was changed from 0.05% by mass to 0.1% by mass. By repeating the method, flurbiprofen-containing hydrous patch 4 was obtained. When the obtained flurbiprofen-containing hydrous patch 4 was subjected to a drug stability test according to Test Example 1, the drug content rate% was 92.3%. Further, the drug permeability when the drug permeability test was conducted according to Test Example 2 was 27.7 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Example 5)
In Example 1, the same preparation as in Example 1 except that 0.5% by mass of polysorbate 80 was changed to 1.0% by mass of polysorbate 60 and sorbitan sesquioleate was changed from 0.05% by mass to 0.1% by mass. By repeating the method, flurbiprofen-containing hydrous patch 5 was obtained. When the obtained flurbiprofen-containing hydrous patch 5 was subjected to a drug stability test according to Test Example 1, the drug content% was 90.1%. Further, the drug permeability when the drug permeability test was conducted according to Test Example 2 was 24.9 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 1)
In Example 1, except for adding crotamiton 0.5 mass%, the exact same preparation method as Example 1 was repeated, and the hydrous patch 1 was obtained. When the obtained hydrous patch 1 was subjected to a drug stability test according to Test Example 1, the drug content rate% was 84.7%. Further, the drug permeability when the drug permeability test was conducted according to Test Example 2 was 27.9 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 2)
A hydrous patch 2 was obtained by repeating exactly the same preparation method as in Example 1, except that 0.5% by mass of crotamiton and 0.05% by mass of 2-mercaptobenzimidazole were added in Example 1. When the obtained hydrous patch 2 was subjected to a drug stability test according to Test Example 1, the drug content% was 73.9%. Further, the drug permeability when the drug permeability test was conducted according to Test Example 2 was 28.7 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 3)
A hydrous patch 3 was obtained by repeating exactly the same preparation method as in Example 1 except that 0.05 mass% of 2-mercaptobenzimidazole was added in Example 1. When the obtained hydrous patch 3 was subjected to a drug stability test according to Test Example 1, the drug content rate% was 84.5%. In addition, when the drug permeability test was performed according to Test Example 2, the drug permeability was 32.3 μg / cm ² . Furthermore, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 4)
In Example 1, except for adding 2-mercaptobenzimidazole 0.20 mass%, exactly the same preparation method as in Example 1 was repeated to obtain a hydrous patch 4. When the obtained hydrous patch 4 was subjected to a drug stability test according to Test Example 1, the drug content% was 76.8%. Moreover, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 5)
In Example 1, the exact same preparation method as Example 1 except that the polysorbate 80 was changed from 0.5% by mass to 0.2% by mass and the sorbitan sesquioleate was changed from 0.05% by mass to 0.02% by mass. Repeatedly, a hydrous patch 5 was obtained. When the obtained hydrous patch 5 was subjected to a drug stability test according to Test Example 1, the drug content% was 83.2%. Moreover, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 6)
Except for polysorbate 80 and sorbitan sesquioleate in Example 1, the same preparation method as in Example 1 was repeated to obtain a hydrous patch 6. When the obtained hydrous patch 6 was subjected to a drug stability test according to Test Example 1, the drug content% was 83.4%. Moreover, there was no paste residue on the release film when the paste residue test on the release film was performed according to Test Example 3. The results are shown in Table 2.

(Comparative Example 7)
Except that polysorbate 80 was changed from 0.5 mass% to 1.5 mass% in Example 1, the same preparation method as in Example 1 was repeated to obtain a hydrous patch 7. When the obtained water-containing patch 7 was subjected to a paste residue test on a release film according to Test Example 3, there was a paste residue on the release film. The results are shown in Table 2.

  The present invention relates to a flurbiprofen-containing hydrous adhesive patch in which flurbiprofen, which is an active ingredient, is dissolved in a hydrous adhesive base and has excellent drug permeability and drug stability. It can be used for.

Claims (3)

  A flurbiprofen-containing water-containing patch comprising 0.5 to 1.0% by weight of polyoxyethylene sorbitan fatty acid ester and sorbitan sesquioleate.   The flurbiprofen-containing hydrous patch according to claim 1, wherein the polyoxyethylene sorbitan fatty acid ester is at least one selected from polysorbate 20, polysorbate 60, and polysorbate 80.   Furthermore, the water-containing adhesive base contains water, a water-soluble polymer, a cross-linking agent, and a moisturizing / wetting agent, The flurbiprofen-containing water-containing patch according to claim 1 or 2.